The financing round was led by Elbow Beach to support pilot-scale trials of the company waste-to-fuel platform.
"Aviation’s fuel bill is only going one way, and the industry urgently needs alternatives that can scale commercially. Too much SAF technology solves for cleaner fuel without solving for cheaper or more available fuel, largely because it still depends on limited feedstocks like waste cooking oil. Neela’s approach is different as it builds on infrastructure that already exists across Europe, avoiding the capital costs that have held back other SAF players, while its low-energy process gives it a credible route to cost parity with fossil jet fuel. It’s that combination of capital efficiency and genuine potential for commercial deployment that convinced us to lead this round from pre-seed through to pilot."
Winfred reads them overnight, pulls out the facts, checks them against Companies House and files them. It was built by C8VA, who do the same kind of work for other businesses: turning messy, unstructured material into something you can search, count and rely on.
The round was led by Breega to support delivery capacity and team growth.
"Clinical trials are built through a series of interconnected decisions about how a study should be designed and run. Today, much of the knowledge and precedent behind those decisions is scattered across previous trials, siloed teams, internal systems and separate documents. Cori brings that intelligence together into a living blueprint, so teams can make better-informed decisions before avoidable problems become delays, so the science never waits on the process,"
The funding package was led by the Scottish National Investment Bank alongside Scottish Enterprise, PXN Group, and Archangels.
"The Bank is delighted to continue to support the growth of iGii alongside our co-investors PXN Ventures and Archangels and now with the support of Scottish Enterprise. The capital that iGii has attracted is a strong indicator of the exciting potential for its Gii technology and the positive impact it could have in the world."
— Alastair McMillen, Associate Director – Sustainable Places
The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.
"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
